secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2022-04-12T23:59:59+00:00
Accession:  0000950170-22-005597
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology appoints Dr. Itziar Canamasas to Board of Directors, effective April 11, 2022
--------------------------------------------------------------------------------

- Board size increased from six to seven directors; Canamasas appointed as Class II director with term expiring at 2022 Annual Meeting.
- Canamasas is Head of Oncology EMEA at Bayer AG with 20+ years of biopharma experience in commercialization and strategy.
- Granted initial stock option for 24,009 shares vesting monthly over three years, per director compensation policy.
- No arrangements or material transactions between Canamasas and the company other than standard indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017022005597/0000950170-22-005597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017022005597/alxo-20220411.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-005597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer